Regulation of monocyte MMP-9 production by TNF-α and a tumour-derived soluble factor (MMPSF)

British Journal of Cancer

Volumn 78, Issue 6, 1998, Pages 724-732

  Leber, T M ^a   Balkwill, F R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

MMP 9; Monocytes; Ovarian cancer; Tumour necrosis factor alpha

Indexed keywords

BB 2116; ENZYME INHIBITOR; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE STIMULATING FACTOR; PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL LINE; COCULTURE; CONTROLLED STUDY; ENZYME LOCALIZATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0031660472     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.568     Document Type: Article

References (40)

1. Aggarwal BB, Moffat B and Harkins RN (1984) Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 259: 686-691
2. Balkwill F (1991) Cytokines, A Practical Approach. The Practical Approach Series. Oxford University Press: Oxford
3. Bennett TA, Lynam EB, Sklar LA and Rogelj S (1996) Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: functional consequences for neutrophil aggregation. J Immunol 156: 3093-3097
4. Bullen EC, Longaker MT, Updike DL, Benton R, Ladin D, Hou Z and Howard EW (1995) Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 104: 236-240
5. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD and Giavazzi R (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460-464
6. Couet J, Sar S, Jolivet A, Hai MT, Milgrom E and Misrahi M (1996) Shedding of human thyrotropin receptor ectodomain. Involvement of a matrix metalloprotease. J Biol Chem 271: 4545-4552
7. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA and Ware CF (1995) A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 181: 1205-1210
8. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR (1993a) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts (published erratum appears in Cancer Res, 1993, 53: 3652). Cancer Res 53: 2087-2091
9. Davies B, Waxman J, Wasan H, Abel P, Williams G, Klausz T, Neal D, Thomas D, Hanby A and Balkwill F (1993b) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369
10. Drummond AH and Gearing AJ (1996) Matrix metalloproteinases and disease (abstract). FASEB J 10: 754
11. Espevik T and Nissen Meyer J (1986) A highly sensitive cell line. WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95: 99-105
12. Feehan C, Darlak K, Kahn J, Walcheck B, Spatola AF and Kishimoto TK (1996) Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. Identification with an L-selectin-alkaline phosphatase reporter. J Biol Chem 271: 7019-7024
13. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM and Wooley K (1994) Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370: 555-557
14. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM and Wooley K (1995) Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 57: 774-777
15. Gery I and Schmidt JA (1985) Human interleukin I. Methods Enzymol 116: 456-467
16. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL and Rees RC (1994) Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69: 177-182
17. Karelina TV, Goldberg GI and Eisen AZ (1995) Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors. J Invest Dermatol 105: 411-417
18. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K and Yagita H (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182: 1777-1783
19. Kiener PA, Moran Davis P, Rankin BM, Wahl AF, Aruffo A and Hollenbaugh D (1995) Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155: 4917-4925
20. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC and Smyth JF (1988) Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 48: 6166-6172
21. Leber TM and Balkwill FR (1997) Zymography: a single step staining method for quantitation of proteolytic activity on substrate gels. Anal Biochem 249: 24-28
22. Liabakk NB, Talbot I, Smith RA, Wilkinson K and Balkwill F (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56: 190-196
23. Liotta LA and Stetler Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054s-5059s
24. Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125
25. Matrisian LM (1992) The matrix-degrading metalloproteinases. Bioessays 14: 455-463
26. Mauch C, Krieg T and Bauer EA (1994) Role of the extracellular matrix in the degradation of connective tissue. Arch Dermatol Res 287: 107-114
27. Mauviel A (1993) Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 53: 288-295
28. Mullberg J, Durie FH, Otten Evans C, Alderson MR, Rose John S, Cosman D, Black RA and Mohler KM (1995) A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 155: 5198-5205
29. Murphy G (1995) Matrix metalloproteinases and their inhibitors. Acta Orthop Scand Suppl 266: 55-60
30. Naylor MS, Stamp GW, Foulkes WD, Eccles D and Balkwill FR (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91: 2194-2206
31. Naylor MS, Stamp GW, Davies BD and Balkwill FR (1994) Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58: 50-56
32. Okada Y, Tsuchiya H, Shimizu H, Tomita K, Nakanishi I, Sato H, Seiki M, Yamashita K and Hayakawa T (1990) Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor alpha. Biochem Biophys Res Commun 171: 610-617
33. Sang QX, Birkedal Hansen H and Van Wart HE (1995) Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochem Biophys Acta 1251: 99-108
34. Sarén P, Welgus HG and Kovanen PT (1996) TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 157: 4159-4165
35. Schmidt JA (1984) Purification and partial biochemical characterization of normal human interleukin 1. J Exp Med 160: 772-787
36. Stetler Stevenson WG (1996) Dynamics of matrix turnover during pathological remodeling of the extracellular-matrix. Am J Pathol 148: 1345-1350
37. Talbot DC and Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A: 2528-2533
38. Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J 5: 2145-2154
39. Woessner JF Jr and Gunja Smith Z (1991) Role of metalloproteinases in human osteoarthritis. J Rheumatol Suppl 27: 99-101
40. Yam LT, Li CY and Crosby WH (1971) Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol 55: 283-290